GCM
CORT icon

Gladius Capital Management’s Corcept Therapeutics CORT Stock Holding History

Gladius Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,098
Closed -$35.7K – 335
2023
Q4 		$35.7K Buy
+1,098
New +$30.1K 0.01% 241
2022
Q3 		– Sell
-1,288
Closed -$31K – 400
2022
Q2 		$31K Buy
+1,288
New +$28.1K ﹤0.01% 295

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Gladius Capital Management's CORT Position: Q1 2024 in Review

Gladius Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 1,098 shares — an estimated $35.7K sold.

Gladius Capital Management first reported a position in CORT in Q2 2022 and held it in 2 quarters. The position peaked at $35.7K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Gladius Capital Management reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Gladius Capital Management sold 1,098 Corcept Therapeutics shares in Q1 2024, an estimated $35.7K.
  • Gladius Capital Management first reported a position in Corcept Therapeutics in Q2 2022 and held it in 2 quarters.
  • Gladius Capital Management's Corcept Therapeutics position peaked at $35.7K in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Gladius Capital Management's 13F filing for Q1 2024, filed 14 May 2024.